

OCT 30 2003 11:26AM HOLLAND & KNIGHT

# HOLLAND & KNIGHT LLP

One Atlantic Center  
1201 West Peachtree Street, N.E.  
Suite 2000  
Atlanta, Georgia 30309-3400

404-817-8500  
404-881-0470 Fax  
[www.hklaw.com](http://www.hklaw.com)

NO. 7762 P. 1

RECEIVED  
CENTRAL FAX CENTER

OCT 30 2003

## FACSIMILE

Annapolis  
Atlanta  
Bethesda  
Boston  
Bradenton  
Chicago\*  
Fort Lauderdale  
Jacksonville  
Lakeland  
Los Angeles  
Miami  
New York  
Northern Virginia  
Orlando  
Portland  
Providence  
St. Petersburg  
San Antonio  
San Francisco  
Seattle  
Tallahassee  
Tampa  
Washington, D.C.  
West Palm Beach  
International Offices:  
Caracas\*\*  
Helsinki  
Mexico City  
Rio de Janeiro  
São Paulo  
Tel Aviv\*\*  
Tokyo  
\*Holland & Knight LLC  
\*\*Representative Office

OFFICIAL

**TO:**

Commissioner for Patents	U.S. Patent and Trademark Office	703-872-9806
NAME	COMPANY/FIRM	FAX NUMBER
Alexandria	VA	703-308-0196
CITY	STATE	(TELEPHONE NUMBER)

**FROM:**

Patrea L. Pabst	404-817-8473	6
NAME	TELEPHONE	TOTAL PAGES (Including Cover Sheet)

**FOR THE RECORD:**

DATE: October 30, 2003	URGENCY: <input type="checkbox"/> SUPER RUSH	<input checked="" type="checkbox"/> RUSH	<input type="checkbox"/> REGULAR
FAXED BY: Pam Turnbough	FILE #: 077829/00006	CLIENT NAME: LEN 102	

CONFIRMED: <input type="checkbox"/> YES <input checked="" type="checkbox"/> NO	NAME:	TIME:
If you did not receive all of the pages or find that they are illegible, please call (404) 817-8500		
<b>CONFIDENTIALITY NOTICE:</b> This facsimile, along with any documents, files, or attachments, may contain information that is confidential, privileged, or otherwise exempt from disclosure. If you are not the intended recipient or a person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, printing, distribution or use of any information contained in or attached to this facsimile is strictly prohibited. If you have received this facsimile in error, please immediately notify us by facsimile or by telephone collect at the numbers stated above, and destroy the original facsimile and its attachments without reading, printing, or saving in any manner. Your cooperation is appreciated. Thank you.		

**MESSAGE:**

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: M. Rigdon Lentz  
Serial No.: 09/709,045 Group Art Unit: 1647  
Filed: November 10, 2000 Examiner: J. Seharaseyv  
For: **METHOD AND SYSTEM TO REMOVE CYTOKINE INHIBITOR IN PATIENTS**

Further to our transmission of an Amendment and Response to Office Action on October 29, 2003, attached is the Declaration of Mark D. Howell and Cheryl L. Selinsky, which was inadvertently omitted from the transmission. Please attach the declaration. Thank you for your attention.

# 612600\_v1

OCT 30 2003 11:26AM HOLLAND & KNIGHT

02/28/2001 10:44

570 410 388

FROM

NO. 7762 P. 2  
(MON) 02 19' 01 17:05, 17:03/NO. 356168386 P 2

IN THIS UNITED STATES PATENT AND TRADEMARK OFFICE

OFFICIAL

In Re the Application of:  
HOWELL et al.  
Serial No.: 09/444,144  
Filed: November 20, 1999  
Attorney File No.: 4369-1  
(formerly Cyte001)  
For: METHOD FOR ENHANCING  
IMMUNE RESPONSES IN  
MAMMALS

) Group Art Unit: 1642

) Examiner: Helms, L.

RECEIVED  
CENTRAL FAX CENTER


OCT 30 2003

DECLARATION OF  
MARK D. HOWELL AND  
CHERYL L. SELINSKY  
(37 CFR § 1.132)

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted  
to the Patent and Trademark Office on February 20, 2001.

SHERIDAN ROSE P.C.

  
KATHLEEN BUSSELL

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

We, Mark D. Howell and Cheryl L. Selinsky, each declare as follows:

1. I am a co-inventor of the above-referenced patent application and am familiar with the application.
2. This Declaration is being submitted in conjunction with an Amendment and Response After Final Rejection to an Office Action having a mailing date of December 20, 2000.
3. The following discussion is provided in traverse of the Examiner's rejection of Claims 1-3, 5, 10-27, 34, 37-38, 40-42, and 50-56 under 35 U.S.C. § 103. These comments have been discussed with the Examiner in the telephone interview of February 6, 2001, and this Declaration is provided at the Examiner's suggestion.

Discussion of Lentz

The Examiner contends that Lentz teaches the separation of blood into a plasma component and a cellular component. While Lentz acknowledges that it is possible to separate plasma from the blood, it is submitted that *Id.* also discourages such a separation of blood (see col. 1, lines 51-62) on the basis that such a separation "has a serious impact on the platelet level in the blood," "could not be considered for widespread use," and is "not very attractive for clinical use." Therefore, the Lentz reference, at best, is highly ambiguous on this point.

OCT. 30. 2003 11:26AM HOLLAND & KNIGHT  
02/28/2003 10:04

FROM

NO. 7762 P. 3  
(MON) 02. 19' 01 17:05/ST. 17:03/NO. 3561683380 P 3

Second, a separation of cellular and acellular components offers no benefit if used in the method of Lentz. Lentz teaches a method of treating whole blood by passing the blood through a filter that separates factors in the blood based on size. Therefore, there is no advantage to be obtained by first separating the blood into cellular and acellular components, and then passing the components over the filter. Indeed, such a separation would be an added and unnecessary step in the method of Lentz. As such, the use of Lentz by the Examiner as a teaching of an element of plasma separation in the stated rejection under 35 U.S.C. § 103 is not appropriate because the teachings of Lentz are, at most, ambiguous, and further, because no advantage in the Lentz process is obtained by separating cellular and acellular components of whole blood. Therefore, Lentz does not provide any motivation to combine the ambiguous discussion in Lentz with the other cited references in the manner suggested by the Examiner.

In contrast to Lentz, and in further support of the non-obviousness of the method claimed in the present application, there are significant advantages not recognized or suggested by the prior art to separating the acellular fraction from the cellular fraction prior to treatment of the bodily fluid. First, it is noted that the present method has the advantage over Lentz of selectively removing the targeted immune system inhibitor without affecting the action of desirable immune system stimulators and other blood components. This advantage is significantly enhanced by treating only the acellular portion of the blood. Specifically, certain of the molecules targeted for removal by the method of the present invention are soluble components which typically bind to an immune system stimulator. These soluble components often are homologues of another binding partner for the immune system stimulator, such that the interaction between the immune system stimulator and the other binding partner is inhibited by the binding of the soluble component to the immune system stimulator. Since the other binding partner is frequently a cell-associated binding partner (i.e., is present on cell surfaces), it is desirable, and indeed, may be highly advantageous, to bind the soluble immune system inhibitor without binding the homologous cell-associated binding partner. For example, sTNFRI is a soluble receptor for TNF $\alpha$  and TNF $\beta$ , which is produced through a proteolytic cleavage of the membrane receptor (mTNFRI) for TNF $\alpha$  and  $\beta$ . This proteolysis releases the extracellular domain of the mTNFRI from the cell surface and allows it to diffuse freely into the extracellular space. The sTNFRI, thus produced, retains fully the ability to bind TNF  $\alpha$  and  $\beta$  with high affinity. Binding of TNF $\alpha$  and  $\beta$  by the sTNFRI prevents TNF $\alpha$  and  $\beta$  from binding to the

OCT. 30. 2003 11:27AM HOLLAND & KNIGHT  
02/28/2001 10:00 370-410-0000  
FROM

NO. 7762 P. 4  
(MON) 02 19' 01 17:00 - F. 17:03/N0. 3501683386 P 4

mTNFRI. Consequently, the pro-inflammatory and apoptotic effects normally induced through the crosslinking of sTNFRI by TNF $\alpha$  and  $\beta$  also are inhibited. Due to the significant structural similarity between sTNFRI and mTNFRI, contact of whole blood with a binding partner reactive with sTNFRI would permit binding to both the sTNFRI in circulation and the mTNFRI present on cell surfaces. This would have dire consequences for the patient, and would contradict the goals of the present method for several reasons. First, binding of the binding partner to mTNFRI would block its engagement by TNF $\alpha$  and  $\beta$ , thus, effectively reducing TNF-induced immune responses. Second, binding of an immobilized binding partner to mTNFRI would effect the depletion of mTNFRI-bearing leukocytes from whole blood, thereby diminishing immune competence. Third, and most undesirable, binding of an immobilized binding partner to mTNFRI would crosslink the receptor and act, therefore, as an agonist of TNF $\alpha$  and  $\beta$ . This would produce very significant and potentially fatal toxicities similar to those observed in human clinical trials of infusional TNF $\alpha$ .

By separating the whole blood into acellular and cellular components in the claimed method, these issues are avoided and the advantages of selectively removing the targeted immune system inhibitor while maintaining the action of desirable immune stimulators and other blood components is achieved. Since Lentz does not teach or suggest any selective removal of any specific factor, these advantages can not be realized by the method of Lentz.

#### Discussion of Selinsky

The Examiner contends that the reference of Selinsky et al. teach that the soluble TNFRI is removed by Ultraphoresis [sic], and that with the knowledge of Lentz, one would know that soluble immune system inhibitors can be removed from whole blood. The Examiner has also pointed to the statement in Selinsky et al.: "[w]e, therefore, propose the development of methods and/or reagents capable of specifically removing sTNFRI, or antagonizing its effects *in situ*, as unconventional, yet promising, strategies for cancer immunotherapy."

It is submitted that, although the statement in Selinsky et al. may cause one of skill in the art to consider how to antagonize or remove sTNFRI *in situ*, such a statement is merely an invitation to experimentation and opens the door for one of skill in the art to consider a wide range of possible approaches. Indeed, Selinsky et al. provide absolutely no guidance as to how one of skill in the art would go about such a task, but rather generally state that the "therapeutic utility of manipulating

OCT. 30. 2003 11:27AM HOLLAND & KNIGHT  
02/28/2001 15:44 510-510 0000  
FROM

NO. 7762 P. 5  
(MON) 02/19/01 17:06:31 17:03/NO. 3561683386 P. 5

sTNFRI levels *in vivo* has been demonstrated" and that "sTNFRI effectively inhibits immune responses *in vivo* and...its modulation is a legitimate therapeutic avenue." It is submitted that one of skill in the art, when presented with an invitation to manipulate the effects of a soluble protein, would look to a variety of conventional approaches to remove or manipulate the effects of that soluble protein *in vivo*, because such approaches are the most clinically desirable means of treating a patient. Conventional therapeutic manipulation of the immune system typically involves the administration of an antibody, peptide, protein, or small molecule that is designed to have a particular action in the patient. In fact, significant research has been directed to systems that enable the delivery of such reagents, including liposomes, targeting antibodies, combinations of liposomes and antibodies, small particles, emulsions, and other vehicles.

One conventional approach to modulating an immune response *in vivo* is to introduce into the subject a reagent that achieves the goal of selectively antagonizing or removing a target molecule once it is administered to a subject. For example, one method for removing or blocking the action of a soluble protein *in vivo* is to administer an antibody that binds to and effectively neutralizes the action of the target protein. Alternatively, a peptide or other soluble binding partner that competes with the target protein for binding to the natural ligand can be administered. As yet another alternative, a small molecule could be designed that targets and neutralizes the action of the target protein. Drug design for such *in vivo* applications is a common therapeutic approach when a target such as a soluble protein is available.

In contrast, to turn to an *ex vivo* approach such as that claimed in the present application is not conventional, and indeed, would be much less likely to be considered because it would conventionally be considered to be less direct, more expensive, and more invasive than the *in vivo* approaches discussed above. Such a method requires far greater manipulation of the patient and of the critical bodily fluids of the patient than an *in vivo* approach. Therefore, to arrive at the claimed *ex vivo* method would not have been an obvious extension of the statements made in Selinsky et al., that are referenced above.

4. I hereby declare that all statements made herein of my own are true, and that all statements made on information and belief are believed to be true; and further that the statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code, and that

OCT. 30, 2003 11:27AM HOLLAND & KNIGHT

02/28/2001 10:44

NO. 7762 P. 6

FROM

(MON) 02.19.01 17:06 ST. 17:03/N0. 3561683388 P 6

such willful false statements may jeopardize the validity of the subject application or any patent issuing therefrom.

2/20/01

Date

Mark D. Howell

Mark D. Howell

2/20/01

Date

Cheryl L. Selinsky

Cheryl L. Selinsky